On Friday the FDA approved the use of Carfilzomib(now named Kyprolis) for use in refractory myeloma. This was reported in the attached article in the Myeloma Beacon at http://www.myelomabeacon.com/news/2012/07/20/fda-approves-kyprolis-carfilzomib-for-relapsed-and-refractory-multiple-myeloma/, and another article in the Wall Street Journal at http://online.wsj.com/article/SB10000872396390444330904577539031234823376.html, which also outlined the importance of the work of the MMRF, Multiple Myeloma Research Foundation, in helping to develop these new drugs. The MMRF has played a key role in providing the support and financing for new multiple myeloma drug development. It is safe to say that they will be a key element in the work to find the "Cure".
Previously, this drug has been available to only a small percentage of the Myeloma patient community, and approval was based on a 266 patient study. I do not include unapproved drugs in the clinical trial area of the home page of www.myelomasurvial.com, but you will now be seeing some great results for those for Carfilzomib in the near future. There have been some excellent results to date, and Carfilzomib will now be more widely available to all patients who can meet the criteria for refractory myeloma. One of my readers has asked me to include a section for treatments for relasped (it has come back but will be treated with a previously used treatment), refractory(it has come back and no longer responds to the old treatment, but others may or may not be available), and high risk patients(those that have a very difficult form of myeloma that proves difficult to find a viable treatment plan). I now think it is time to expand the site to include this subset of patients. So you can expect to see this in the next several months.
Just wanted to share the great news. Best Regards/editor@myeloma survival.com
Previously, this drug has been available to only a small percentage of the Myeloma patient community, and approval was based on a 266 patient study. I do not include unapproved drugs in the clinical trial area of the home page of www.myelomasurvial.com, but you will now be seeing some great results for those for Carfilzomib in the near future. There have been some excellent results to date, and Carfilzomib will now be more widely available to all patients who can meet the criteria for refractory myeloma. One of my readers has asked me to include a section for treatments for relasped (it has come back but will be treated with a previously used treatment), refractory(it has come back and no longer responds to the old treatment, but others may or may not be available), and high risk patients(those that have a very difficult form of myeloma that proves difficult to find a viable treatment plan). I now think it is time to expand the site to include this subset of patients. So you can expect to see this in the next several months.
Just wanted to share the great news. Best Regards/editor@myeloma survival.com
RSS Feed